UT 34
Alternative Names: SARD UT-34; UT-34Latest Information Update: 28 May 2025
At a glance
- Originator University of Tennessee Research Foundation
- Developer Oncternal Therapeutics, Inc.; University of Tennessee Research Foundation
- Class Antiandrogens; Small molecules
- Mechanism of Action Androgen receptor antagonists; Androgen receptor degradation enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA
- 10 Apr 2021 Preclinical trials in Triple negative Breast cancer in USA (unspecified route) before April 2021
- 10 Apr 2021 Efficacy and pharmacodynamics data from a preclinical trial in triple-negative Breast cancer presented at the 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)